Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
Cynata Therapeutics share price jumps 14% on COVID-19 trial
Healthcare Shares
Is this ASX biotech share the next CSL?
Share Market News
Afterpay and Mesoblast were among the most traded shares on the ASX last week
Share Market News
Tech shares race to record highs as Bank of America tips BHP and Rio shares
Share Gainers
The Starpharma share price jumps on new partnership deal
Healthcare Shares
Up 230% in a year! Is the Mesoblast share price a buy?
Share Market News
Take a look at last week's best performing ASX shares
Share Market News
ASX 200 rises 0.6%, Mesoblast soars
Healthcare Shares
Why I'd buy today's CSL share price over Mesoblast
Share Gainers
Why Baby Bunting, Evolution, Mesoblast, & Xero shares are zooming higher
Share Market News
ASX 200 up 0.3%: NAB Q3 update, Mesoblast rockets, Newcrest guidance disappoints
Share Gainers
Mesoblast share price rockets 57% higher on FDA breakthrough
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
